Addressing IOP and QOL With LAL, iStent, and Dextenza

Show Description +

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Addressing IOP and QOL With LAL, iStent, and Dextenza

I. Paul Singh, MD, discusses the current technologies available to maintain good quality of life (QOL) for patients while also aggressively managing IOP. In this case, the patient had a history of primary open-angle glaucoma and monovision. Dr. Singh demonstrates the implantation of an Light Adjustable Lens (LAL, RxSight) and iStent (Glaukos) with use of Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix).

Posted: 2/27/2023

Please log in to leave a comment.

More in Glaucoma

Exploring Surgical Options for a Young Glaucoma Patient

Rachel G. Simpson, MD; Roya Garakani, DO; and Craig J. Chaya, MD

Introducing the Elara 900

Iqbal Ike K. Ahmed, MD, FRCSC

The Evolving Landscape of Viscodilation

Iqbal Ike K. Ahmed, MD, FRCSC; Arsham Sheybani, MD; and Christine M. Funke, MD